Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

From the monthly archives: April, 2018

We are pleased to present below all posts archived in 'April, 2018'. If you still can't find what you are looking for, try using the search box.

Congratulations to Public Health England (PHE) for winning the British Expertise International Awards 2018

Congratulations to Public Health England (PHE) for winning the British Expertise International Awards 2018 under “international healthcare project” category for “Fast-track global collaborations to conquer emergencies such as Ebola and Zika”.  PHE’s Senior Business Development Manager Professor S.S. Vasan collected the award on his team’s behalf from HRH The Duke of Gloucester KG GCVO on 12 April 2018. Thanking his colleagues “who have made such a difference to our response to Ebola and Zika crises”, Professor Vasan said, “The aspect of our project we are most proud of is collaborations. It is absolutely essential when you are facing a global emergency like Ebola or Zika that we set aside differences, and we keep the focus on saving lives and working in collaboration with industry, academia and non-profit sector so that the response can be very effective and very quick. Every minute saves lives, literally, in this case.”      & ...

Read the rest of entry »

OBN concludes hugely successful BioTrinity 2018 conference

Leading annual life sciences event attracted more than 160 company CEOs, in excess of 150 leading investors and over 80 major pharmaceutical company delegates

Read the rest of entry »

Driven by rapid growth Oxford Sciences Innovation expands to The Oxford Science Park

OSI builds on links with Park as second occupier of prestigious Schrödinger Building

Read the rest of entry »

PATH and Mologic advance new malaria test

Seattle, Washington, April 17, 2018—PATH and United Kingdom-based test developer Mologic have entered an agreement to advance a new rapid diagnostic test to support treatment and elimination of Plasmodium vivax, or relapsing, malaria.

Read the rest of entry »

Sustained Episomal Gene Expression Free from Foreign DNA

AMSBIO announces MC-Easy™ minicircle technology for labs looking to produce sustained transgene expression in model animal generation and gene therapy research without the risks of introducing exogenous DNA.

Read the rest of entry »

Wickham Labs Announces Upcoming Webinar on Regulatory Changes in Medical Device Development

Come join Wickham Laboratories and Patient Guard for this free webinar on May 23rd to discuss Regulatory Changes in Medical Device Development.

Read the rest of entry »

BioDivide Ltd Announces New Website Launch

The new website offers visitors rich insights into the Company’s lead stem cell product, StemPlanTM, and applied expertise of the therapeutic and biotechnology applications of stem cells.BioDivide Limited (“BioDivide” or the “Company), a world leader in stem cell and regenerative medicines, products, tools, technologies and services, announced today the launch of its new website. The Company’s unique and innovative stem cell product, StemPlan, is a feature in the new website. StemPlan, is a stem cell therapy approved by the UK Veterinary Medicine’s Directorate that uses a non-invasive proprietary and innovative method of collecting stem cells. Not offered by any other company, StemPlan uniquely provides horse owners with readily available stem cell therapy when they need it most.

The new website offers a comprehensive understanding of stem cell therapy and how regenerative medicine leads to repair of injured or diseased tissue to restore normal function. The website also provides a complete overview of the Company’s GMP facilities and service offerings engineered to harness the power of stem cells and regenerative medicine. BioDivide’s commitment to quality and biologicals manufacturing capabilities are emphasised in the new site.  The new website goes live today and is located at

 “We are excited about our new website launch and the comprehensive information it provides about BioDivide’s exclusive products and services” said Dr Erik Miljan, BioDivide’s founder and Chief Executive Officer. “We believe that this new site provides valuable information about stem cell therapy to the public and our customers”.

“Not all stem cells are the same. Manufacturing a top quality stem cell product requires understanding the biology and process that will give you different characteristics, whether consistency, purity or potency, added Dr Miljan.”

BioDivide provides the highest quality stem cell supportive therapy products and services. The Company’s quality systems incorporate needle-to-needle traceability for the complete supply chain. Visitors are encouraged to explore the new website to learn more about stem cells and regenerative medicine.

University of Birmingham to lead Midlands Innovation Commercialisation of Research Accelerator (MICRA)

The University of Birmingham is to lead a connected system of incubators and accelerators that will drive jobs and economic growth across the Midlands region, following a £5 million award announced today by Research England.

Read the rest of entry »

University spinouts – an imperfect ecosystem

The start of April marked the official launch of UK Research and Innovation (UKRI), an amalgamation of the seven research councils, Innovate UK and Research England. With this, UK universities’ ability to turn research into innovation is once again under the spotlight.

Read the rest of entry »

Edinburgh-based life science company, Neurocentrx have appointed two industry heavyweights to their board to help take the company to a global market

Neurocentrx are developing new uses and methods of administration for ketamine. Historically, ketamine has been used as an anaesthetic, but recent research shows this drug can also be used to help with pain management, such as required by cancer patients during treatment, and also psychiatric conditions such as depression.

Until now ketamine has not been suitable to treat these symptoms and conditions, but Neurocentrx are developing a new oral capsule format, that is easy to dose control, and can even be administered outside of a hospital environment, allowing countless more patients to be able to take advantage of the benefits this drug has now been proven to offer. 

Nigel Brooksby and Dr Tim Corn have both joined the board, bringing with them significant experience from their previous high-profile roles in the healthcare and pharmaceutical sector, so it’s fantastic to see Neorocentrx receiving this great support as the company reaches this exciting new phase.

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.